Status:
COMPLETED
In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Adults)
Lead Sponsor:
Fugeia NV
Conditions:
Healthy
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The investigational study product used in this clinical trial is a soft drink containing an arabinoxylan-oligosaccharides (AXOS) preparation extracted from wheat bran (hereafter called Wheat Bran Extr...
Eligibility Criteria
Inclusion
- Male or female 18-90 years of age, inclusive
- Regular eating habits
- Body Mass Index (BMI) between 18.5 and 30 kg/m2
- Consent to take in the study product according to the study protocol
- Subject is willing to maintain his or her habitual food and beverage intake throughout the study period (with the exception of omission of prebiotic and probiotic food products as indicated in the study protocol)
- For female volunteers of childbearing potential: not planning to become pregnant during the clinical trial and willing to commit to the use of a medically approved form of contraception
Exclusion
- Low-calorie diet or other extreme dietary habits in the 6 weeks before the start of the clinical trial
- Recent use of antibiotics
- Abdominal surgery in the past
- Serious illness within 3 months of start of clinical trial
- Use of medication or dietary supplements known to influence GI tract within two weeks of start of clinical trial. Examples of such medication/dietary supplements are antispasmodics, anti diarrhea medication and/or probiotic medication
- Complete anesthetics within 1 month of the start of the clinical trial
- Chronic GI conditions such as inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), chronic constipation, history of frequent diarrhea, clinically important lactose intolerance
- Allergy for wheat products
- Celiac disease
- For female volunteers: pregnant or lactating
- Alcohol abuse
- Smoking more than 5 cigarettes per day
- Subject has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the subject at undue risk.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01002651
Start Date
March 1 2009
End Date
October 1 2009
Last Update
October 27 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000